Why the study?
Does treatment-resistant depression increase health-related quality of life burden compared to non-treatment-resistant MDD in UK patients?
Does treatment-resistant depression increase health-related quality of life burden compared to non-treatment-resistant MDD in UK patients?
Treatment-resistant depression imposes a greater health-related quality of life burden than non-treatment-resistant major depressive disorder, highlighting the need for better treatment options.
Answers are grounded in this paper and cite their sources.
May warrant closer HRQoL monitoring in TRD; leaves open whether targeted therapies reduce this burden.
TRD is associated with an added patient HRQoL burden, above that observed for non-treatment-resistant MDD. This highlights the unmet need for greater access to improved treatment, including new treatment options for Patients-TRD.
No takes yet. Share an insight, caveat, or question.
Rathod et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: